trial

Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia

NCTId NCT00328276
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 20
Sponsored by China Medical University Hospital
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
20
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-12
Primary completion
—
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Sarcosine

Sponsors

China Medical University HospitalLead Sponsor
National Health Research Institutes, TaiwanCollaborator
National Science and Technology Council, TaiwanCollaborator

Investigators

2
Hsien-Yuan Lane, MD.PhD.Principal Investigator
Guochuan E. Tsai, MD,PhDStudy Director

Sites

1 total
Taichung, Taiwan

Facts & assertions

3 sourced
Enrollment
20
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Sarcosine
drug
lead_sponsor
China Medical University Hospital
company
collaborator
National Health Research Institutes, Taiwan
company
National Science and Technology Council, Taiwan
company
indication
Psychotic Disorders
indication
Schizophrenic Disorders
indication
Schizophrenias
indication
investigator
Hsien-Yuan Lane, MD.PhD.
person
Guochuan E. Tsai, MD,PhD
person